Viewing Study NCT01631669


Ignite Creation Date: 2025-12-24 @ 11:14 PM
Ignite Modification Date: 2025-12-25 @ 8:49 PM
Study NCT ID: NCT01631669
Status: UNKNOWN
Last Update Posted: 2012-07-03
First Post: 2012-06-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification
Sponsor: Walter Reed National Military Medical Center
Organization:

Study Overview

Official Title: Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial
Status: UNKNOWN
Status Verified Date: 2012-06
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Hypotheses:

H1: Celecoxib, when given less than five days after injury will result in a statistical decrease in the incidence and/or severity of radiographically apparent Heterotopic Ossification when compared to controls.

H2a: A biomarker profile will accurately predict which patients in the treatment group will respond to Celecoxib prophylaxis for Heterotopic Ossification.

H2b: A biomarker profile will accurately predict which patients in the control group are at highest risk of developing Heterotopic Ossification
Detailed Description: This study is a prospective, randomized, controlled clinical trial.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
110587 OTHER FDA IND View